Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
SCYNEXISFRA:135 +1.40%40 Debt-to-Equity is 0.03 as of Jun. 2026, which is 94% below its 10-year median of 0.51. GuruFocus rates FRA:135 with a GF Score™ of 40/100 and a GF Value™ of €14.60. The stock has 3 warning signs investors should review. Among 812 Drug Manufacturers companies, SCYNEXIS ranks better than 88.79% on this metric.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for SCYNEXIS's Debt-to-Equity or its related term are showing as below:
FRA:135'
s Debt-to-Equity Range Over the Past 10 Years
Min: -1.64 Med: 0.51 Max: 15.03
Current: 0.03
During the past 13 years, the highest Debt-to-Equity Ratio of SCYNEXIS was 15.03. The lowest was -1.64. And the median was 0.51.
FRA:135's Debt-to-Equity is ranked better than 88.79% of 812
companies
in the Drug Manufacturers industry
Industry Median: 0.275
vs FRA:135: 0.03
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
SCYNEXIS Debt-to-Equity Related Terms
SCYNEXIS Debt-to-Equity Historical Data
* Premium members only.
The historical data trend for SCYNEXIS's Debt-to-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:135 vs IXHL, ETST, INIS: Debt-to-Equity Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, SCYNEXIS's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
SCYNEXIS Debt-to-Equity vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, SCYNEXIS's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where SCYNEXIS's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SCYNEXIS (FRA:135) has a Debt-to-Equity of 0.03 as of Jun. 2026. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on SCYNEXIS and its competitors. This is 94% below median its historical median of 0.51. According to the industry distribution chart, SCYNEXIS ranks #91 out of 812 companies in the Drug Manufacturers industry, placing it in the top 11.2%.
Is SCYNEXIS's Debt-to-Equity too high?
SCYNEXIS's current Debt-to-Equity of 0.03 is 94% below median its 10-year median of 0.51. The Drug Manufacturers industry median Debt-to-Equity is 0.28. SCYNEXIS's value of 0.03 is 89.1% below this industry median. Based on the distribution chart, SCYNEXIS ranks #91 out of 812 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, SCYNEXIS has a GF Score™ of 40/100, reflecting its overall financial health beyond just this single metric.
How does SCYNEXIS's Debt-to-Equity compare to IXHL and ETST?
According to the Drug Manufacturers industry distribution chart, SCYNEXIS ranks #91 out of 812 companies for Debt-to-Equity. This places SCYNEXIS in the top 11% of its industry — outperforming the majority of peers. The industry median Debt-to-Equity is 0.28. SCYNEXIS's value of 0.03 is 89.1% below this benchmark. While the company's 10-year median is 0.51 vs. the industry median of 0.28, SCYNEXIS has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Drug Manufacturers company?
The median Debt-to-Equity among Drug Manufacturers companies is 0.28, based on 812 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. SCYNEXIS's current Debt-to-Equity of 0.03 is 89.1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on SCYNEXIS and its competitors. For the Drug Manufacturers industry, the median Debt-to-Equity is 0.28 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. SCYNEXIS's current Debt-to-Equity is 0.03, which is 94% below median its own 10-year median of 0.51. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is SCYNEXIS stock overvalued right now?
SCYNEXIS (FRA:135) has a current Debt-to-Equity of 0.03. The stock's GF Value™ is €14.60, compared to a current price of €4.36 — trading 70.2% below its estimated fair value. The current Debt-to-Equity is 0.03, which is 94% below median its 10-year median of 0.51 and 89.1% below the Drug Manufacturers industry median of 0.28. SCYNEXIS's overall GF Score™ is 40/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For SCYNEXIS (FRA:135), the current Debt-to-Equity is 0.03 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is SCYNEXIS (FRA:135) Overvalued in 2026?
Based on GuruFocus' analysis, SCYNEXIS stock appears to be undervalued.
The current stock price of €4.36 is trading 70.2% below its estimated GF Value™ of €14.60.
Key valuation signals for FRA:135:
Debt-to-Equity: 0.03 (94% below median its 10-year median of 0.51)
GF Value™: €14.60 vs. price of €4.36 (70.2% below fair value)
Industry Position: 89.1% below the Drug Manufacturers median (#91 of 812)
No single metric tells the full story. See the FRA:135 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address unmet therapeutic needs. It is engaged in developing a product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. The ibrexafungerp is a novel and structurally distinct triterpenoid glucan synthase inhibitor that is effective in vitro and in vivo against broad range of Candida and Aspergillus species, including drug-resistant strains as well as Pneumocystis, Coccidioides, Histoplasma and Blastomyces genera and some common mucorales species.
40GF Score
Get the complete analysis for FRA:135
Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:135 has been successfully added to your 
